timothy sykes logo
Hims & Hers Gains Momentum with Novo Nordisk Partnership Expansion Thumbnail
ADD US ONG Google News

Hims & Hers Gains Momentum with Novo Nordisk Partnership Expansion

TIM SYKES•UPDATED MAR. 10, 2026, 4:03 PM ET
Reviewed by Bryce Tuohey Fact-checked by Matt Monaco

Hims & Hers Health Inc. stocks have been trading up by 6.27 percent, powered by positive market sentiment.

Candlestick Chart

Live Update At 16:03:04 EDT: On Tuesday, March 10, 2026 Hims & Hers Health Inc. stock [NYSE: HIMS] is trending up by 6.27%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

The financial tapestry of Hims & Hers exhibits a dynamic narrative filled with both challenges and opportunities. As of recent reports, their integrated telehealth platform exhibited significant strides in the weight-loss sector. Revenues surged in recent quarters with a notable $2.35 billion reported. The profitability ratios reveal a healthy gross margin of 73.8%, while the earnings before interest, taxes, depreciation, and amortization (EBITDA) margin is holding steady at 7.5%. Despite some operational headwinds, the strategic expansions seem to align well with their long-term financial outlook.

Recent upticks in their stock price, primarily due to collaborations like the one with Novo Nordisk, underline an optimism shared by both investors and analysts alike. The price-to-sales ratio stands at 1.53, a fair valuation given their increasing revenue streams and strong market performance. Another point of interest is the steady increase in their assets turnover, currently at 1.6, indicating more efficient asset utilization amid growing sales.

Investor Confidence on the Rise

In the context of a thriving weight-loss market, Hims & Hers has struck a gold mine by partnering with a key player, Novo Nordisk. This alliance involves distributing GLP-1 drugs, such as Ozempic and Wegovy, marking a pivotal transition towards FDA-sanctioned treatments on their platform.

The strategic direction of Hims, as highlighted by key research analysts, points to an astute response to market demands, reflecting positively on stock valuation. Nephron Research upgraded their forecast, setting a $35 price target, an encouraging figure that signals long-term potential amidst a maturing market space.

More Breaking News

Critically, as legal hurdles dissipate with the termination of lawsuits, the company anticipates an unimpeded path to becoming a formidable player within the telehealth sphere. Such positive trends amplify the chances of Hims taking a prominent role nationally and internationally.

Market Reactions

Market reactions to this new collaboration have been overwhelmingly positive. Stock upgrades have emerged in response, driving the stock upward by substantially double-digit percentages over recent days. The removal of legal obstacles has largely contributed to the confidence that brokers express in the firm’s ambitious roadmap.

A jump in stock prices, approximately 46% during premarket trading, is a testament to the market’s approval of Hims & Hers’ new strategies. Bolstered by analyst forecasts, citing generous future revenue streams from the partnership, Hims is strategically well-aligned with market trends that are drawn uncompromisingly towards telehealth and pharmaceutical synergies. An unprecedented spike in investor participation further underscores a broad acceptance of its growth path.

Conclusion

In conclusion, the amalgamation between Hims & Hers and Novo Nordisk as strategic partners represents a formidable blend of innovative healthcare technologies and established market presence in weight-loss medications. Positive market sentiment and trader enthusiasm highlight a significant win for Hims amid evolving patient-expectations and associated market shifts. The resulting interest and uptick in stock price only galvanize this development’s potential impact on the company’s future trajectory. As new pharmaceutical products launch via their platform and as trust grows among traders, Hims enters a promising chapter, embedding confidence throughout their corporate strategies. As millionaire penny stock trader and teacher Tim Sykes, says, “It’s better to go home at zero than to go home in the red.” This philosophy underpins the cautious optimism traders feel about the partnership. As we look to the future, both immediate and long-term, this collaboration shines as an exemplar of strategic corporate alliances in the digital health space.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading HIMS

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”